Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
5 lessons
12mThe only peptides with large controlled trials for weight loss are the GLP-1 class: semaglutide, tirzepatide, and the oral options approved in 2025 and 2026. Retatrutide is next but still investigational. Here's how they work, what the trials showed, and how to access them through a licensed clinician.
8mFoundayo is the brand name for orforglipron — a once-daily oral small-molecule GLP-1 approved in April 2026. Here's what the pill is, how it differs from injectables, and what trials studied — not a dosing prescription.
7mThe first small-molecule oral GLP-1 option removes injection training and cold-chain handling, but daily dosing creates a different adherence job.
8mThe loudest peptide stories are moving at different speeds. PCAC recommendations await FDA action, oral GLP-1 access is real, and the next obesity programs still have filing or review milestones ahead.
8mOrforglipron is Lilly's once-daily oral small-molecule GLP-1. Here's the titration ladder searchers want — 1 mg start, step-ups every four weeks, and Phase 3 maintenance doses.
Also available at /blog for legacy links.